SenesTech, Inc. (SNES) Stock: Is This Biotechnology Stock Worth Your Investment?

0

SenesTech, Inc. (SNES) is making a move down in the market today. The stock, one that is focused on the biotechnology space, is currently priced at $0.95 after tumbling -5.99% so far today. When it comes to biotech stocks, there are several aspects that have the potential to cause price movement in the market. One of the most common is news. Here are the most recent trending headlines surrounding SNES:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-04-19 09:00AM SenesTech to Present at the 21st Annual Global Investment Conference on September 9, 2019
Aug-27-19 09:00AM ContraPest® Deployment in Los Angeles, CA
Aug-20-19 12:04PM What Kind Of Shareholder Appears On The SenesTech, Inc.’s (NASDAQ:SNES) Shareholder Register?
Aug-13-19 04:05PM SenesTech Announces Second Quarter 2019 Financial and Operational Results
07:50AM SenesTech’s Earnings Outlook

However, any time investors are making an investing decision, investors should look into much more than news, this is especially the case in the speculative biotech industry. Here’s what’s happing when it comes to SenesTech, Inc..

Returns That SNES Investors Have Seen

While a decline in a single session, like the fall that we’re seeing from SenesTech, Inc. may make some investors fearful, a single session decline by itself should not be the reason for a decision to, or not to, invest in a stock. It’s generally important to dig into trends experienced by the stock further out than a single trading session. When it comes to SNES, here are the returns that we have seen:

  • Past Seven Days – In the past seven days, SNES has produced a change in price amounting to -15.97%.
  • Past Month – The ROI from SenesTech, Inc. over the past month has been -32.49%.
  • Quarterly – Throughout the last three months, the stock has produced a ROI of -28.61%
  • Past Six Months – Over the past 6 months, investors have seen a change of -19.53% from the company.
  • YTD – Since the close of last year SNES has generated a ROI of 62.25%.
  • Full Year – Finally, over the past full year, investors have seen movement of 23.96% out of SNES. Throughout this period, the stock has traded at a high of -51.31% and a low price of 72.64%.

Rations That Traders Should Consider

Digging into a few ratios having to do with a company can give investors an understanding of just how dangerous and/or potentially profitable a an investment option might be. Here are some of the key ratios to think about when digging into SNES.

Short Ratio – The short ratio is a tool that’s used by investors to measure the amount of short interest. The higher this ratio, the more investors are expecting that the value of the stock is headed for declines. Across the sector, biotech stocks can come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the space. Nonetheless, when it comes to SenesTech, Inc., it’s short ratio is 5.10.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure If a company is able to pay for its debts when they come due based on quick assets or current assets. In the biotech industry, several companies rely on the continuation of investor support, the quick and current ratios can be bad. Nonetheless, quite a few gems in the biotechnology sector do have strong current and quick ratios. When it comes to SNES, the quick and current ratios add up to 2.60 and 3.70 respectively.  

Book To Share Value – The book to share value compares the book value of assets owned by the company to the share price. In this case, the book to share value ratio works out to 0.16.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to consider. In the case of SNES, the cash to share value ratio comes to 0.

What Analysts Think About SenesTech, Inc.

While it’s never a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their analysis when validating your own due diligence when it comes to making an investment decision in the biotechnology industry. Here are the most recent moves that we have seen from analysts as it relates to SNES.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Are Big Money Players Doing With SenesTech, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SNES, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutional investors own 7.60% of the company. However, it’s important to note that institutional ownership has changed in the amount of 4.27% throughout the last 3 months.
  • Insiders – As far as insiders go, those close to the company currently hold 5.30% of SenesTech, Inc.. Insider ownership of the company has changed by 68.64% in the last quarter.

Looking At Share Counts

Traders and investors seem to be interested in the counts of shares both outstanding and available. In regard to SenesTech, Inc., currently there are 28.57M with a float of 25.77M. This means that out of the total of 28.57M shares of SNES that are out there today, 25.77M are able to trade hands on the market.

It’s also important to take a look at the short percentage of the float. After all, if a large portion of the float available for trading is sold short, the overall opinion among investors is that the company is going to fall hard. When it comes to SNES, the percentage of the float that is sold short is 4.23%. Most investors would say that a concerning short percent of the float would be considered to be anything over 40%. However, I’ve seen that a short ratio over 26% is probably going to be a a play that could prove to be very risky.

Financial Performance

What have ween seen from SNES in terms of financial results?Here’s the data:

  • Analyst Expectations – At the moment, analysts have expectations that the company will come up with earnings per diluted share of -0.29, with -0.10 being reported in the earnings announcement for the current quarter. Although this data is not earnings driven, since we’re chatting about Wall St. analysts, SNES is presently rated a 2.00 considering a scale that ranges from 1 to 5 on which 1 is the poorest possible Wall Street analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Over the last 5 years, SenesTech, Inc. has created a change in sales volume in the amount of 0. Earnings per share through the last 5 years have seen movement in the amount of 0.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is generally explained in the human world, SenesTech, Inc. has created a earnings change by 62.20%. SenesTech, Inc. has also moved the needle in regard to sales in the amount of -33.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I am incredibly dependent on my human counterparts. After all, humans built me! Although, my creators made it possible for me to learn by myself, it is quite a bit simpler to do so when I receive feedback from human beings. Below this article, you’ll find a section for comments. If you’d like for me dig into other data, change the way in which I write something, look at something from an alternative perspective, or you’re interested in teaching me anything else, I’d love to learn. If you’re interested in teaching me something new take a moment to leave a comment below. I will read your lesson and I will use it to evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here